- Home
- IMVT vs MKTX Comparison
IMVT vs MKTX Comparison
Compare IMVT & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMVT | MKTX |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.0B |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | IMVT | MKTX |
|---|---|---|
| Price | $27.33 | $192.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $30.78 | ★ $204.44 |
| AVG Volume (30 Days) | ★ 1.3M | 559.4K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 1.69% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 6.64 |
| Revenue | N/A | ★ $397,471,000.00 |
| Revenue This Year | N/A | $10.06 |
| Revenue Next Year | N/A | $7.20 |
| P/E Ratio | ★ N/A | $27.93 |
| Revenue Growth | N/A | ★ 7.45 |
| 52 Week Low | $12.72 | $156.17 |
| 52 Week High | $29.25 | $232.84 |
Technical Indicators
Market Signals| Indicator | IMVT | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 73.04 |
| Support Level | $24.63 | $177.38 |
| Resistance Level | $27.71 | $192.91 |
| Average True Range (ATR) | 1.14 | 5.39 |
| MACD | 0.11 | 1.60 |
| Stochastic Oscillator | 55.65 | 94.36 |
Price Performance
Historical ComparisonAbout IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.